Clinical trials: Systemic Sclerosis, Diffuse
Scleroderma
Taking Charge of Systemic Sclerosis
This Study is a collaborative project with partners (people with scleroderma and stakeholders) designed to refine an internet program for patients with scleroderma and to compare the internet program to an authoritative…
- Trial name
- TOSS (NCT02494401)
- Testing
- Internet-based self-management program, Scleroderma book
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- University of Michigan
Rheumatoid Arthritis, Psoriatic Arthritis
Mindfulness Based Stress Reduction in Rheumatic Diseases
This study will assess the mental health and clinical benefits of Mindfulness Based Stress Reduction (MBSR) in patients with rheumatic disease who have anxiety or depression.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
- Trial name
- MBSR (NCT03411057)
- Testing
- Mindfulness Based Stress Reduction (MBSR), Control
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Systemic Sclerosis, Fibromyalgia
Effects of Fibromyalgia Syndrome in Patients With Systemic Sclerosis
Systemic sclerosis [SSc]; is a multisystem disease characterized by immune activation, microvascular disease and fibroblast dysfunction, which is thought to occur as a result of complex and not fully understood interaction…
- Trial name
- NCT04411498
- Testing
- Fibromyalgia diagnosis in patients with SSc
- Where
- Turkey (Türkiye)
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Raynaud Disease
Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
The purpose of this study is to determine if Vascana, a novel topical formulation of nitroglycerin, is effective in the treatment and prevention of the symptoms associated with Raynaud's Phenomenon.
- Trial name
- NCT00934427
- Testing
- 0.9% nitroglycerin in TAM cream, vehicle cream
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- MediQuest Therapeutics
Diffuse Cutaneous Systemic Sclerosis
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc).
- Trial name
- RESOLVE-1 (NCT03398837)
- Testing
- Lenabasum 5 mg, Lenabasum 20 mg
- Where
- 74 sites in United States, Australia and 10 more
- Volunteers
- 365 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis
This protocol is of a systematic review for risk factors of pulmonary arterial hypertension in systemic sclerosis.
- Trial name
- NCT03889509
- Where
- Canada
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Healthy, Idiopathic Inflammatory Myopathies
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases.
- Conditions
- Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease
- Trial name
- NCT07284797
- Testing
- XmAb657
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Systemic Sclerosis
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this…
- Trial name
- NCT07047690
- Testing
- Nemolizumab
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 162 people
- Sponsor
- Galderma R&D
Morphea, Scleroderma, Localized
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
A two-component therapeutic consisting of FCX-013 and veledimex for the treatment of localized scleroderma (or morphea). The first component, FCX-013, is autologous human fibroblasts genetically-modified using lentivirus and…
- Conditions
- Morphea, Scleroderma, Localized, Scleroderma
- Trial name
- NCT03740724
- Testing
- FCX-013, veledimex
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Castle Creek Biosciences, LLC.
Scleroderma, Systemic Sclerosis
The Scleroderma Patient-centered Intervention Network (SPIN) Support Group Leader Education Program Feasibility Trial
Many people living with a rare disease turn to peer-led support groups to cope with their condition and access educational resources.
- Trial name
- SPIN-SSLED-F (NCT03508661)
- Testing
- SPIN-SSLED Program
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Lady Davis Institute
Raynaud's Disease
Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Raynaud's phenomenon or patients…
- Trial name
- NCT00266669
- Testing
- Topical organogel with nitroglycerin
- Where
- 19 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- MediQuest Therapeutics
Systemic Sclerosis With and Without Interstitial Lung Disease
A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.
- Trial name
- NCT04948554
- Testing
- MK-2225
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 5 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Scleroderma, System; Sclerosis
Rehabilitation Program in Patients With Scleroderma
Scleroderma (or Systemic Sclerosis - SSc) is one of the most neglected diseases worldwide, according to the World Health Organization.
- Conditions
- Scleroderma, System; Sclerosis, Muscle Strain, Physical Disability
- Trial name
- NCT05041868
- Testing
- Treatment
- Where
- Brazil
- Volunteers
- 104 people
- Sponsor
- Centro Universitário Augusto Motta
Scleroderma, Systemic Sclerosis
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Scleroderma, or systemic sclerosis (SSc), is a diffuse connective tissue disease characterized by changes in the skin, blood vessels, skeletal muscles, and internal organs.
- Trial name
- NCT00040651
- Testing
- Fludarabine, Cyclophosphamide, Thymoglobulin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Scleroderma, Dysphagia
Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing
FLIP topography has been FDA cleared to evaluate a variety of esophageal conditions, but has never been evaluated in patients with scleroderma.
- Conditions
- Scleroderma, Dysphagia, GERD - Gastro-Esophageal Reflux Disease
- Trial name
- NCT03270722
- Testing
- FLIP topography, Upper Endoscopy
- Where
- United States
- Sponsor
- Stanford University
Scleroderma
Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea
This is a study designed to evaluate the comparative effectiveness of topical medications for the treatment of circumscribed morphea.
- Trial name
- NCT02680717
- Testing
- Clobetasol, Calcipotriene, Tacrolimus
- Sponsor
- Medical College of Wisconsin
Diffuse Cutaneous Systemic Sclerosis
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic sclerosis (dcSSc) who relapsed after discontinuation…
- Trial name
- NCT05149768
- Testing
- Brentuximab vedotin
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Scleroderma
Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
This phase I/II pilot trial seeks to demonstrate that prolonged administration of Campath-1H without prior marrow or stem cell harvesting can result in immunoablation similar to that achieved by hematopoietic stem cell…
- Trial name
- CAMPATH-1H (NCT01639573)
- Testing
- Campath
- Sponsor
- Children's Hospital Los Angeles
Rheumatoid Arthritis, Spondyloarthritis
Pregnancy and Medically Assisted Conception in Rare Diseases
Rare diseases frequently affect women of childbearing age. Pregnancy in these women has become less rare, but remains associated with high levels of complications.
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- EGR2 (NCT02450396)
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis
Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma.
Diffuse infiltrating pneumonia (DIP) is a severe complication of systemic sclerosis and one of the leading cause of death in this condition.
- Trial name
- SCLERO-PID (NCT03271333)
- Testing
- lung function tests
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- University Hospital, Lille